Addition of Navitoclax Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis
December 5th 2020Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.